Full Press Release Details
[excerpt] The early successors in cell therapy have mostly been CAR-T therapies, with the T standing for T cells. But T cells aren’t the only option for cell therapy. Promising work is being done with natural killer, or NK cells, a different kind of immune system cell that could work even better in some ways.
On this pharmaphorum podcast, Dr. Fred Aslan, Artiva’s CEO talks with host Jonah Comstock about the potential of NK cells as an allogeneic cell therapy approach in autoimmune disease and the importance of a robust manufacturing process.
Find episode 126 (dated May 30, 2024) on iTunes , Spotify , and Stitcher or on pharmaphorum’s website , which has a podcast player or the option to download the episode.